Prostate cancer tissue is masked by bicalutamide: a case report.
Prostate cancer is the most common malignant tumor in men. Recently, a slightly decreased frequency of margin positivity following neoadjuvant bicalutamide treatment due to tumor shrinkage was reported. Trials investigating other anti-androgens in the past also reported lower frequencies of surgical margin positivity, but patients outcome has not improved. In this case, local recurrence was confirmed by needle biopsy in a patient five years following radical prostatectomy for prostate adenocarcinoma. After therapy with 50 mg bicalutamide for a month, the tumour was resected. Despite of detailed histological work-up and immunohistochemistry cancer suspicious lesions were not found. We think that bicalutamide may be capable of masking prostate cancer cells.
Ellinger
J
J
Klinik und Poliklinik für Urologie, Universitätsklinikum Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany. joerg.ellinger@ukb.uni-bonn.de
Bastian
P J
PJ
Biermann
K
K
Schmidt
M E
ME
Textor
J
J
Bollmann
D
D
Zhou
H
H
Müller
S C
SC
D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D000726:Androgen Antagonists / Q000009:adverse effects*; D000813:Anilides / Q000009:adverse effects*; D001707:Biopsy, Needle; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000473:pathology*; D009570:Nitriles / Q000009:adverse effects*; D011467:Prostate / Q000187:drug effects; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D014105:Tosyl Compounds / Q000009:adverse effects*
D000726:Androgen Antagonists; D000813:Anilides; D009570:Nitriles; D014105:Tosyl Compounds; C053541:bicalutamide; D017430:Prostate-Specific Antigen